Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-01-30

AUTHORS

P. Cacoub, V. Descamps, O. Meyer, C. Speirs, P. Belissa-Mathiot, P. Musette

ABSTRACT

We have reviewed 47 drug rash with eosinophilia and systemic symptoms (DRESS) cases associated to strontium ranelate reported up to March 2011 to the Marketing Holder. The main signs were skin rash, fever, face oedema hypereosinophilia and liver involvement. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained, and DRESS was identified as the direct cause of death in one case. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95 % CI (1/14,859; 1/42,194)] newly treated patients in France. Because DRESS is a severe drug reaction, the occurrence of a rash in a patient treated with strontium ranelate should lead to prompt and permanent treatment discontinuation.IntroductionThis study aims to describe cases of DRESS reported to the Marketing Authorisation Holder worldwide for patients receiving strontium ranelate by practitioner or by regulatory authorities.MethodsSpontaneously reported hypersensitivity events from the strontium ranelate pharmacovigilance database since marketing authorisation (2004) to March 2011 were reviewed by an expert committee. Cases of DRESS were classified as established, probable, possible or no DRESS according to expert judgement. National incidences of DRESS were estimated in relation to the number of newly treated patients.ResultsUp to March 2011, 325 cases of strontium ranelate-induced hypersensitivity events were assessed from which 47 DRESS cases were confirmed. Mean age was 68.7 years and besides skin rash, the main signs and symptoms were hypereosinophilia, liver involvement, fever and face oedema. Median time to skin reaction was 33.5 days after treatment start. Most patients (62 %) recovered at the time of reporting or were recovering. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained. Relapses were observed in a single case. The mortality rate was 8.5 %. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95 % CI (1/14,859; 1/42,194)] newly treated patients in France.ConclusionDRESS is a well-identified and characterised adverse reaction to strontium ranelate. This risk should be integrated in the risk-benefit balance evaluation of patient treatment, and the occurrence of a rash should lead to prompt and permanent treatment discontinuation with careful follow-up. More... »

PAGES

1751-1757

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00198-013-2265-1

DOI

http://dx.doi.org/10.1007/s00198-013-2265-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043038400

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23361875


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Eruptions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Hypersensitivity", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Eosinophilia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Europe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pharmacovigilance", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "UMR 7211 (UPMC/CNRS) and U 959 (INSERM), Pierre and Marie Curie (Paris 6) University, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.462844.8", 
          "name": [
            "AP-HP, Department of Internal Medicine, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, 83 Boulevard de l\u2019hopital, 75013, Paris, France", 
            "UMR 7211 (UPMC/CNRS) and U 959 (INSERM), Pierre and Marie Curie (Paris 6) University, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cacoub", 
        "givenName": "P.", 
        "id": "sg:person.01356022604.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356022604.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, AP-HP, Bichat-Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Dermatology, AP-HP, Bichat-Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris Cit\u00e9, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Descamps", 
        "givenName": "V.", 
        "id": "sg:person.0701162743.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701162743.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Rheumatology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meyer", 
        "givenName": "O.", 
        "id": "sg:person.01313450420.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313450420.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fetcham, Leatherhead, Surrey, UK", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Fetcham, Leatherhead, Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Speirs", 
        "givenName": "C.", 
        "id": "sg:person.01127214356.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127214356.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Les Laboratoires Servier, Suresnes, France", 
          "id": "http://www.grid.ac/institutes/grid.418301.f", 
          "name": [
            "Les Laboratoires Servier, Suresnes, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Belissa-Mathiot", 
        "givenName": "P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, Rouen University Hospital and INSERM Unit 905, Rouen, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Dermatology, Rouen University Hospital and INSERM Unit 905, Rouen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Musette", 
        "givenName": "P.", 
        "id": "sg:person.0651004530.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651004530.27"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00002018-200730110-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047378816", 
          "https://doi.org/10.2165/00002018-200730110-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-010-1369-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024292861", 
          "https://doi.org/10.1007/s00198-010-1369-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00128071-200304080-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007753205", 
          "https://doi.org/10.2165/00128071-200304080-00006"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-01-30", 
    "datePublishedReg": "2013-01-30", 
    "description": "We have reviewed 47 drug rash with eosinophilia and systemic symptoms (DRESS) cases associated to strontium ranelate reported up to March 2011 to the Marketing Holder. The main signs were skin rash, fever, face oedema hypereosinophilia and liver involvement. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained, and DRESS was identified as the direct cause of death in one case. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95\u00a0% CI (1/14,859; 1/42,194)] newly treated patients in France. Because DRESS is a severe drug reaction, the occurrence of a rash in a patient treated with strontium ranelate should lead to prompt and permanent treatment discontinuation.IntroductionThis study aims to describe cases of DRESS reported to the Marketing Authorisation Holder worldwide for patients receiving strontium ranelate by practitioner or by regulatory authorities.MethodsSpontaneously reported hypersensitivity events from the strontium ranelate pharmacovigilance database since marketing authorisation (2004) to March 2011 were reviewed by an expert committee. Cases of DRESS were classified as established, probable, possible or no DRESS according to expert judgement. National incidences of DRESS were estimated in relation to the number of newly treated patients.ResultsUp to March 2011, 325 cases of strontium ranelate-induced hypersensitivity events were assessed from which 47 DRESS cases were confirmed. Mean age was 68.7\u00a0years and besides skin rash, the main signs and symptoms were hypereosinophilia, liver involvement, fever and face oedema. Median time to skin reaction was 33.5\u00a0days after treatment start. Most patients (62\u00a0%) recovered at the time of reporting or were recovering. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained. Relapses were observed in a single case. The mortality rate was 8.5\u00a0%. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95\u00a0% CI (1/14,859; 1/42,194)] newly treated patients in France.ConclusionDRESS is a well-identified and characterised adverse reaction to strontium ranelate. This risk should be integrated in the risk-benefit balance evaluation of patient treatment, and the occurrence of a rash should lead to prompt and permanent treatment discontinuation with careful follow-up.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00198-013-2265-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100834", 
        "issn": [
          "0937-941X", 
          "1433-2965"
        ], 
        "name": "Osteoporosis International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "permanent treatment discontinuation", 
      "cases of DRESS", 
      "strontium ranelate", 
      "drug rash", 
      "hypersensitivity events", 
      "treatment discontinuation", 
      "skin rash", 
      "liver involvement", 
      "maximum incidence", 
      "severe drug reactions", 
      "main signs", 
      "time of reporting", 
      "most patients", 
      "treatment start", 
      "face edema", 
      "median time", 
      "mean age", 
      "systemic symptoms", 
      "drug reactions", 
      "DRESS cases", 
      "skin reactions", 
      "adverse reactions", 
      "pharmacovigilance database", 
      "national incidence", 
      "rash", 
      "patients", 
      "mortality rate", 
      "ranelate", 
      "marketing authorisation holder", 
      "patient treatment", 
      "symptom cases", 
      "symptoms", 
      "marketing authorisation", 
      "incidence", 
      "hypereosinophilia", 
      "single case", 
      "eosinophilia", 
      "discontinuation", 
      "fever", 
      "authorisation holders", 
      "Expert Committee", 
      "direct cause", 
      "balance evaluation", 
      "signs", 
      "involvement", 
      "edema", 
      "relapse", 
      "cases", 
      "death", 
      "age", 
      "treatment", 
      "risk", 
      "cause", 
      "regulatory authorities", 
      "persistence", 
      "days", 
      "occurrence", 
      "events", 
      "years", 
      "reporting", 
      "latest news", 
      "evaluation", 
      "study", 
      "Committee", 
      "start", 
      "database", 
      "practitioners", 
      "time", 
      "rate", 
      "reaction", 
      "authorisation", 
      "number", 
      "France", 
      "dress", 
      "news", 
      "relation", 
      "judgments", 
      "authorities", 
      "holder", 
      "expert judgment", 
      "systemic symptoms (DRESS) cases", 
      "Marketing Holder", 
      "face oedema hypereosinophilia", 
      "oedema hypereosinophilia", 
      "DRESS symptoms", 
      "strontium ranelate pharmacovigilance database", 
      "ranelate pharmacovigilance database", 
      "strontium ranelate-induced hypersensitivity events", 
      "ranelate-induced hypersensitivity events", 
      "ConclusionDRESS", 
      "risk-benefit balance evaluation"
    ], 
    "name": "Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate", 
    "pagination": "1751-1757", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043038400"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00198-013-2265-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23361875"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00198-013-2265-1", 
      "https://app.dimensions.ai/details/publication/pub.1043038400"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:28", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_600.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00198-013-2265-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00198-013-2265-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00198-013-2265-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00198-013-2265-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00198-013-2265-1'


 

This table displays all metadata directly associated to this object as RDF triples.

268 TRIPLES      22 PREDICATES      134 URIs      123 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00198-013-2265-1 schema:about N235ea216aebf473f856388706e0439b2
2 N2405e28fbe1344a5ad97cde286593c15
3 N255e3a884326427491e01b78984e5165
4 N3aec88f40781484a92aadb6e76fc7d1c
5 N4d771b9a4ebb4d6fa987dabbc6b83a85
6 N7ba694dd6c0b4536a5094aa9d6f05dc7
7 N81d510ba3ea248caad121667b13c364e
8 N91bf28a736c54e388a2000f3a2f597e4
9 N9729713e07794e14a86df0662b516c33
10 Na2ef9bec2f1a46359cd16eb81eb1f6d9
11 Nbb575fc41df74d679c95791888ee2b2e
12 Nc1dd321afdb747ffb7c77c93472663d8
13 Nd4ca2851d9364a55a49b265034b2fcee
14 Nf3a06376862245209e55526f6e9306d1
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author Neb8227b3b3504d6c9930b4428d6a40db
18 schema:citation sg:pub.10.1007/s00198-010-1369-0
19 sg:pub.10.2165/00002018-200730110-00003
20 sg:pub.10.2165/00128071-200304080-00006
21 schema:datePublished 2013-01-30
22 schema:datePublishedReg 2013-01-30
23 schema:description We have reviewed 47 drug rash with eosinophilia and systemic symptoms (DRESS) cases associated to strontium ranelate reported up to March 2011 to the Marketing Holder. The main signs were skin rash, fever, face oedema hypereosinophilia and liver involvement. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained, and DRESS was identified as the direct cause of death in one case. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95 % CI (1/14,859; 1/42,194)] newly treated patients in France. Because DRESS is a severe drug reaction, the occurrence of a rash in a patient treated with strontium ranelate should lead to prompt and permanent treatment discontinuation.IntroductionThis study aims to describe cases of DRESS reported to the Marketing Authorisation Holder worldwide for patients receiving strontium ranelate by practitioner or by regulatory authorities.MethodsSpontaneously reported hypersensitivity events from the strontium ranelate pharmacovigilance database since marketing authorisation (2004) to March 2011 were reviewed by an expert committee. Cases of DRESS were classified as established, probable, possible or no DRESS according to expert judgement. National incidences of DRESS were estimated in relation to the number of newly treated patients.ResultsUp to March 2011, 325 cases of strontium ranelate-induced hypersensitivity events were assessed from which 47 DRESS cases were confirmed. Mean age was 68.7 years and besides skin rash, the main signs and symptoms were hypereosinophilia, liver involvement, fever and face oedema. Median time to skin reaction was 33.5 days after treatment start. Most patients (62 %) recovered at the time of reporting or were recovering. For ten patients, persistence of DRESS symptoms was reported at the latest news obtained. Relapses were observed in a single case. The mortality rate was 8.5 %. The maximum incidence of DRESS associated with strontium ranelate was 1/24,112 [95 % CI (1/14,859; 1/42,194)] newly treated patients in France.ConclusionDRESS is a well-identified and characterised adverse reaction to strontium ranelate. This risk should be integrated in the risk-benefit balance evaluation of patient treatment, and the occurrence of a rash should lead to prompt and permanent treatment discontinuation with careful follow-up.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N22eae4f0d8874341b1af8330bb5bc477
28 N9ecebd879dfb4cebb4ca65c5d07a3d12
29 sg:journal.1100834
30 schema:keywords Committee
31 ConclusionDRESS
32 DRESS cases
33 DRESS symptoms
34 Expert Committee
35 France
36 Marketing Holder
37 adverse reactions
38 age
39 authorisation
40 authorisation holders
41 authorities
42 balance evaluation
43 cases
44 cases of DRESS
45 cause
46 database
47 days
48 death
49 direct cause
50 discontinuation
51 dress
52 drug rash
53 drug reactions
54 edema
55 eosinophilia
56 evaluation
57 events
58 expert judgment
59 face edema
60 face oedema hypereosinophilia
61 fever
62 holder
63 hypereosinophilia
64 hypersensitivity events
65 incidence
66 involvement
67 judgments
68 latest news
69 liver involvement
70 main signs
71 marketing authorisation
72 marketing authorisation holder
73 maximum incidence
74 mean age
75 median time
76 mortality rate
77 most patients
78 national incidence
79 news
80 number
81 occurrence
82 oedema hypereosinophilia
83 patient treatment
84 patients
85 permanent treatment discontinuation
86 persistence
87 pharmacovigilance database
88 practitioners
89 ranelate
90 ranelate pharmacovigilance database
91 ranelate-induced hypersensitivity events
92 rash
93 rate
94 reaction
95 regulatory authorities
96 relapse
97 relation
98 reporting
99 risk
100 risk-benefit balance evaluation
101 severe drug reactions
102 signs
103 single case
104 skin rash
105 skin reactions
106 start
107 strontium ranelate
108 strontium ranelate pharmacovigilance database
109 strontium ranelate-induced hypersensitivity events
110 study
111 symptom cases
112 symptoms
113 systemic symptoms
114 systemic symptoms (DRESS) cases
115 time
116 time of reporting
117 treatment
118 treatment discontinuation
119 treatment start
120 years
121 schema:name Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate
122 schema:pagination 1751-1757
123 schema:productId N1dd3174afc8140f89c8a5dffafd2ee83
124 N2641c68df42e4cbe9505952d52e03ff8
125 N35db0af47bf94c39b68fac240816fd93
126 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043038400
127 https://doi.org/10.1007/s00198-013-2265-1
128 schema:sdDatePublished 2021-12-01T19:28
129 schema:sdLicense https://scigraph.springernature.com/explorer/license/
130 schema:sdPublisher N256743d2a1dc4480a01a1b7c17cee236
131 schema:url https://doi.org/10.1007/s00198-013-2265-1
132 sgo:license sg:explorer/license/
133 sgo:sdDataset articles
134 rdf:type schema:ScholarlyArticle
135 N1dd3174afc8140f89c8a5dffafd2ee83 schema:name pubmed_id
136 schema:value 23361875
137 rdf:type schema:PropertyValue
138 N22eae4f0d8874341b1af8330bb5bc477 schema:volumeNumber 24
139 rdf:type schema:PublicationVolume
140 N235ea216aebf473f856388706e0439b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Drug Hypersensitivity
142 rdf:type schema:DefinedTerm
143 N2405e28fbe1344a5ad97cde286593c15 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Drug Eruptions
145 rdf:type schema:DefinedTerm
146 N255e3a884326427491e01b78984e5165 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Eosinophilia
148 rdf:type schema:DefinedTerm
149 N256743d2a1dc4480a01a1b7c17cee236 schema:name Springer Nature - SN SciGraph project
150 rdf:type schema:Organization
151 N2641c68df42e4cbe9505952d52e03ff8 schema:name dimensions_id
152 schema:value pub.1043038400
153 rdf:type schema:PropertyValue
154 N35db0af47bf94c39b68fac240816fd93 schema:name doi
155 schema:value 10.1007/s00198-013-2265-1
156 rdf:type schema:PropertyValue
157 N3aec88f40781484a92aadb6e76fc7d1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Humans
159 rdf:type schema:DefinedTerm
160 N3e98c34d287749128bfedef5ff01898e rdf:first sg:person.01127214356.23
161 rdf:rest N838d6fb0cad843df8f26e732a9882e34
162 N4d771b9a4ebb4d6fa987dabbc6b83a85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Aged
164 rdf:type schema:DefinedTerm
165 N51c963687b0041b1b09c172ab6acec5c rdf:first sg:person.0701162743.32
166 rdf:rest Nd54c366177f2427e9abe463b1f71a2b9
167 N7ba694dd6c0b4536a5094aa9d6f05dc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Europe
169 rdf:type schema:DefinedTerm
170 N81d510ba3ea248caad121667b13c364e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Aged, 80 and over
172 rdf:type schema:DefinedTerm
173 N838d6fb0cad843df8f26e732a9882e34 rdf:first Ndf0e27b3405d443eb5edb13910cee5ef
174 rdf:rest Nb3a853c4770440bdb489660d006448b3
175 N91bf28a736c54e388a2000f3a2f597e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Bone Density Conservation Agents
177 rdf:type schema:DefinedTerm
178 N9729713e07794e14a86df0662b516c33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Female
180 rdf:type schema:DefinedTerm
181 N9ecebd879dfb4cebb4ca65c5d07a3d12 schema:issueNumber 5
182 rdf:type schema:PublicationIssue
183 Na2ef9bec2f1a46359cd16eb81eb1f6d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Male
185 rdf:type schema:DefinedTerm
186 Nb3a853c4770440bdb489660d006448b3 rdf:first sg:person.0651004530.27
187 rdf:rest rdf:nil
188 Nbb575fc41df74d679c95791888ee2b2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Middle Aged
190 rdf:type schema:DefinedTerm
191 Nc1dd321afdb747ffb7c77c93472663d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Pharmacovigilance
193 rdf:type schema:DefinedTerm
194 Nd4ca2851d9364a55a49b265034b2fcee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Adult
196 rdf:type schema:DefinedTerm
197 Nd54c366177f2427e9abe463b1f71a2b9 rdf:first sg:person.01313450420.02
198 rdf:rest N3e98c34d287749128bfedef5ff01898e
199 Ndf0e27b3405d443eb5edb13910cee5ef schema:affiliation grid-institutes:grid.418301.f
200 schema:familyName Belissa-Mathiot
201 schema:givenName P.
202 rdf:type schema:Person
203 Neb8227b3b3504d6c9930b4428d6a40db rdf:first sg:person.01356022604.21
204 rdf:rest N51c963687b0041b1b09c172ab6acec5c
205 Nf3a06376862245209e55526f6e9306d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Thiophenes
207 rdf:type schema:DefinedTerm
208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
209 schema:name Medical and Health Sciences
210 rdf:type schema:DefinedTerm
211 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
212 schema:name Clinical Sciences
213 rdf:type schema:DefinedTerm
214 sg:journal.1100834 schema:issn 0937-941X
215 1433-2965
216 schema:name Osteoporosis International
217 schema:publisher Springer Nature
218 rdf:type schema:Periodical
219 sg:person.01127214356.23 schema:affiliation grid-institutes:None
220 schema:familyName Speirs
221 schema:givenName C.
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01127214356.23
223 rdf:type schema:Person
224 sg:person.01313450420.02 schema:affiliation grid-institutes:None
225 schema:familyName Meyer
226 schema:givenName O.
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01313450420.02
228 rdf:type schema:Person
229 sg:person.01356022604.21 schema:affiliation grid-institutes:grid.462844.8
230 schema:familyName Cacoub
231 schema:givenName P.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356022604.21
233 rdf:type schema:Person
234 sg:person.0651004530.27 schema:affiliation grid-institutes:None
235 schema:familyName Musette
236 schema:givenName P.
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651004530.27
238 rdf:type schema:Person
239 sg:person.0701162743.32 schema:affiliation grid-institutes:None
240 schema:familyName Descamps
241 schema:givenName V.
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0701162743.32
243 rdf:type schema:Person
244 sg:pub.10.1007/s00198-010-1369-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024292861
245 https://doi.org/10.1007/s00198-010-1369-0
246 rdf:type schema:CreativeWork
247 sg:pub.10.2165/00002018-200730110-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047378816
248 https://doi.org/10.2165/00002018-200730110-00003
249 rdf:type schema:CreativeWork
250 sg:pub.10.2165/00128071-200304080-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007753205
251 https://doi.org/10.2165/00128071-200304080-00006
252 rdf:type schema:CreativeWork
253 grid-institutes:None schema:alternateName Department of Dermatology, AP-HP, Bichat-Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris Cité, Paris, France
254 Department of Dermatology, Rouen University Hospital and INSERM Unit 905, Rouen, France
255 Department of Rheumatology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France
256 Fetcham, Leatherhead, Surrey, UK
257 schema:name Department of Dermatology, AP-HP, Bichat-Claude Bernard Hospital, University Paris Diderot, Sorbonne Paris Cité, Paris, France
258 Department of Dermatology, Rouen University Hospital and INSERM Unit 905, Rouen, France
259 Department of Rheumatology, AP-HP, Bichat-Claude Bernard Hospital, Paris, France
260 Fetcham, Leatherhead, Surrey, UK
261 rdf:type schema:Organization
262 grid-institutes:grid.418301.f schema:alternateName Les Laboratoires Servier, Suresnes, France
263 schema:name Les Laboratoires Servier, Suresnes, France
264 rdf:type schema:Organization
265 grid-institutes:grid.462844.8 schema:alternateName UMR 7211 (UPMC/CNRS) and U 959 (INSERM), Pierre and Marie Curie (Paris 6) University, Paris, France
266 schema:name AP-HP, Department of Internal Medicine, Pitié-Salpêtrière Hospital, 83 Boulevard de l’hopital, 75013, Paris, France
267 UMR 7211 (UPMC/CNRS) and U 959 (INSERM), Pierre and Marie Curie (Paris 6) University, Paris, France
268 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...